Angiodynamics Inc.

ANGO

Nasdaq; healthcare; SIC 3841, Surgical & Medical Instruments & Apparatus; CIK 0001275187

D

fourth fifth of 370 graded peers in healthcare

rank 246 of 370; percentile 66.4; sampling error 2.5 points; lower is stronger


A B C D E

D, the sloth




Scoreboard	
Profitability	A/B percentile 22.5
Solvency	C/D percentile 58.5
Growth and financing	D/E percentile 80.4
Reliability	0.87 AUC filers with $120M to $591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025
Peer failure rate	1.03% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$120M to $591M assets total assets $267.2M
Standard universe	inside revenue above $1M and assets above $10M
Warnings	none triggered; fortress balance sheet not computable: dilution, distress
Inputs computable	7 of 14
Graded from	filings received through Sep 29, 2026 41 days before the rescan; latest periodic filing 10-Q received Oct 8, 2026
Last close	$11.73 2026-11-06; market equity $493.5M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Jul 14, 2026

AngioDynamics is a dynamic, diversified medical technology company committed to expanding treatment options and improving patient outcomes and quality of life by designing, manufacturing and selling products and technologies which aid clinicians in the treatment of patients with cardiovascular disease and cancer diagnoses. Our execution strategy is built on innovative R&D, clinical and regulatory pathway expansion and customer centric sales performance. AngioDynamics was founded in Queensbury, N.Y., U.S., in 1988 and began manufacturing and shipping product in the early 1990s. The Company is headquartered in Latham, N.Y., with manufacturing primarily out of the Queensbury facility.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 22.5						
Gross profitability	65.5%	32.3%		14.3	365	2026-05-31
Return on invested capital	not computable	9.3%				

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

latest aligned inputs end 2024-05-31; latest annual assets end 2026-05-31					
Accruals ratio	(14.6%)	(6.6%)	30.7	802	2026-05-31
Gross margin stability, five years	1.4 pts	2.8 pts	22.4	242	2026-05-31
Solvency, sleeve percentile 58.5					
Twelve-month failure probability	not computable	0.08%			
latest liabilities, cash plus short-term investments, book equity, and shares are required					
Altman Z double-prime	(2.65)	(0.37)	48.1	747	2026-05-31
Net debt to EBITDA	not computable	1.82x			
EBITDA must exceed $100,000					
Interest coverage	not computable	(4.51x)			
latest aligned inputs end 2024-05-31; latest annual assets end 2026-05-31					
Current ratio	2.19x	2.94x	68.9	828	2026-05-31
Growth and financing, sleeve percentile 80.4					
Revenue growth, three-year compound	(1.9%)	10.0%	75.9	412	2026-05-31
Free cash flow growth, three-year compound	not computable	10.9%			
current FCF must be positive and base FCF must exceed $100,000					
Reinvestment rate	not computable	37.1%			
pretax income must exceed the validity floor and imply a 0%-100% tax rate					
Asset growth, three years	(20.5%)	2.2%	84.9	696	2026-05-31
Net share issuance, one year	not computable	2.5%			
prior share count is 70 days earlier					


Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Fortress balance sheet	cash minus debt is 76,056,000 USD; Altman Z is not used

Among 370 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
241	Lenz Therapeutics, Inc. (LENZ)	65.0	D	short runway
242	Fulgent Genetics, Inc. (FLGT)	65.3	D	
243	Dentsply Sirona Inc. (XRAY)	65.6	D	
244	Cardiff Oncology, Inc. (CRDF)	65.9	D	short runway, fortress balance sheet
245	AIM ImmunoTech Inc. (AIM)	66.1	D	late filer, degenerate inputs, distress
246	Angiodynamics Inc. (ANGO)	66.4	D	fortress balance sheet
247	Caribou Biosciences, Inc. (CRBU)	66.7	D	short runway, distress
248	Exagen Inc. (XGN)	66.9	D	dilution, fortress balance sheet
249	InspireMD, Inc. (NSPR)	67.2	D	dilution, short runway, distress
250	Alpha Teknova, Inc. (TKNO)	67.5	D	
251	PTC Therapeutics, Inc. (PTCT)	67.8	D	

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

What the price implies

at the 2026-11-06 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	27.8%	(2.1%)	68
Distance from 52-week high	(27.3%)	(30.4%)	52
EBIT to enterprise value	(8.7%)	(1.5%)	35
Free cash flow yield	0.1%	(1.0%)	56
Book value to price	0.33	0.29	55
Sales to price	0.65	0.30	73
Composite equity issuance, five years	9.0%	20.8%	38
Relative strength against the sector, log excess return	0.08	(0.19)	68

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2026-05-31	
Return on assets above zero	fail
Operating cash flow above zero	pass
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	pass
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	$34.0M
Operating cash flow, four quarters	$3.7M
Months of runway	not finite
Days since last periodic filing	32 (10-Q received Oct 8, 2026)
Median daily dollar volume, 63 sessions	$7.2M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	$174.9M	2026-05-31	2026-07-14	10-K	26-048138
2	assets	us-gaap:Assets	$267.2M	2026-05-31	2026-07-14	10-K	26-048138
3	operating income	us-gaap:OperatingIncomeLoss	-$192.4M	2024-05-31	2026-07-14	10-K	26-048138
4	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$191.6M	2024-05-31	2026-07-14	10-K	26-048138
5	income tax	us-gaap:IncomeTaxExpenseBenefit	-$7.3M	2024-05-31	2026-07-14	10-K	26-048138
6	total debt	us-gaap:LongTermDebt	$0	2024-05-31	2024-07-25	10-K	24-032989
7	book equity	us-gaap:StockholdersEquity	$205.6M	2024-05-31	2026-07-14	10-K	26-048138
8	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$76.1M	2024-05-31	2025-07-18	10-K	25-000014
9	total debt	us-gaap:LongTermDebt	$49.8M	2023-05-31	2024-07-25	10-K	24-032989
10	book equity	us-gaap:StockholdersEquity	$378.3M	2023-05-31	2026-07-14	10-K	26-048138
11	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$44.6M	2023-05-31	2024-07-25	10-K	24-032989
12	net income	us-gaap:NetIncomeLoss	-$36.7M	2026-05-31	2026-09-29	10-K/A	26-037995
13	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$3.1M	2026-05-31	2026-07-14	10-K	26-048138
14	assets	us-gaap:Assets	$280.1M	2025-05-31	2026-07-14	10-K	26-048138
15	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$320.2M	2026-05-31	2026-07-14	10-K	26-048138
16	gross profit	us-gaap:GrossProfit	$157.7M	2025-05-31	2026-07-14	10-K	26-048138
17	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$292.5M	2025-05-31	2026-07-14	10-K	26-048138
18	gross profit	us-gaap:GrossProfit	$154.7M	2024-05-31	2026-07-14	10-K	26-048138

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

19	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$303.9M	2024-05-31	2026-07-14	10-K	26-048138
20	gross profit	us-gaap:GrossProfit	$174.2M	2023-05-31	2025-07-18	10-K	25-000014
21	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$338.8M	2023-05-31	2025-07-18	10-K	25-000014
22	gross profit	us-gaap:GrossProfit	$165.7M	2022-05-31	2024-07-25	10-K	24-032989
23	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$316.2M	2022-05-31	2024-07-25	10-K	24-032989
24	current assets	us-gaap:AssetsCurrent	$163.4M	2026-05-31	2026-07-14	10-K	26-048138
25	current liabilities	us-gaap:LiabilitiesCurrent	$74.7M	2026-05-31	2026-07-14	10-K	26-048138
26	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$465.9M	2026-05-31	2026-07-14	10-K	26-048138
27	operating income	us-gaap:OperatingIncomeLoss	-$39.9M	2026-05-31	2026-07-14	10-K	26-048138
28	book equity	us-gaap:StockholdersEquity	$170.8M	2026-05-31	2026-07-14	10-K	26-048138
29	liabilities	us-gaap:Liabilities	$96.3M	2026-05-31	2026-07-14	10-K	26-048138
30	depreciation amortization	us-gaap:Depreciation	$14.7M	2024-05-31	2026-07-14	10-K	26-048138
31	interest expense	us-gaap:InterestExpense	-$1.6M	2024-05-31	2024-07-25	10-K	24-032989
32	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$2.6M	2026-05-31	2026-07-14	10-K	26-048138
33	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$10.1M	2025-05-31	2026-07-14	10-K	26-048138
34	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$4.5M	2025-05-31	2026-07-14	10-K	26-048138
35	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$28.2M	2024-05-31	2026-07-14	10-K	26-048138
36	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$2.5M	2024-05-31	2026-07-14	10-K	26-048138
37	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$78,000	2023-05-31	2025-07-18	10-K	25-000014
38	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$3.8M	2023-05-31	2025-07-18	10-K	25-000014
39	depreciation amortization	us-gaap:Depreciation	$10.5M	2026-05-31	2026-07-14	10-K	26-048138
40	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$36.3M	2026-05-31	2026-07-14	10-K	26-048138
41	income tax	us-gaap:IncomeTaxExpenseBenefit	$442,000	2026-05-31	2026-07-14	10-K	26-048138
42	current assets	us-gaap:AssetsCurrent	$168.3M	2025-05-31	2026-07-14	10-K	26-048138
43	current liabilities	us-gaap:LiabilitiesCurrent	$76.2M	2025-05-31	2026-07-14	10-K	26-048138
44	assets	us-gaap:Assets	$317.7M	2024-05-31	2025-07-18	10-K	25-000014
45	assets	us-gaap:Assets	$532.6M	2023-05-31	2024-07-25	10-K	24-032989
46	shares outstanding	dei:EntityCommonStockSharesOutstanding	42,054,450	2026-09-18	2026-09-29	10-K/A	26-037995
47	shares outstanding	dei:EntityCommonStockSharesOutstanding	41,332,389	2026-07-10	2026-07-14	10-K	26-048138

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.